GlaxoSmithKline and Human Genome see shares rise after getting US FDA advisory panel backing for lupus drug Benlysta
The US Food and Drug Administration’s Arthritis Advisory Committee has voted 13 to two to recommend that the FDA approves Benlysta (belimumab), under development by USA-based Human Genome Sciences (Nasdaq: HGSI) and UK pharmaceutical giant GlaxoSmithKline (LSE: GSK), for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE).
The news saw HGS’s shares, which last Friday plunged 11% when the FDA issued briefing documents raising questions about Benlysta’s safety (The Pharma Letter November 15), jumped 9.5% to $28.35 in after hours activity. Trading in the stock had been halted ahead of the panel discussions. GSK’s American Depositary Receipts gained 2.9% to $39.65 in New York last night and the stock rose 2.3% to £12.41 in early morning London trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze